Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...

BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing ...

On Wednesday, Truist Securities revised its price target for Regeneron Pharmaceuticals stock, traded on (NASDAQ: REGN), lowering it to $975 from the previous target of $1,004.Despite the reduction ...

Citi lowered the firm’s price target on Regeneron (REGN) to $750 from $795 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and ...

TD Cowen cuts Regeneron stock price target to $1,030 ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares. With the shares off about 30% since the surprising news of an ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Barclays lowered the firm’s price target on Regeneron (REGN) to $1,065 from $1,080 and keeps an Overweight rating on the shares post the Q3 report. The firm says recent pressure on Regeneron ...

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform rating on the shares. The company reported Q3 revenue in ...

On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, and sharply reduced the stock’s price target to $662 from ...